Trial Profile
A Study to Evaluate the Effect of Metal Cation-Containing Antacids on 1200 mg QD Raltegravir Pharmacokinetics in HIV-Infected Subjects on a Stable Raltegravir-Containing Regimen.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 31 May 2017
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary) ; Aluminium hydroxide/magnesium hydroxide; Calcium carbonate
- Indications HIV infections
- Focus Adverse reactions; Pharmacokinetics
- 31 May 2017 New trial record